Cinacalcet therapy and cardiovascular risk in hemodialysis patients
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2012, Vol 66, Issue 0
Abstract
Patients with end-stage kidney disease are at high cardiovascular risk due to accelerated atherosclerosis development. Important factors that accelerate the development of atherosclerosis in this group are calcium-phosphorus disturbances causing vascular calcification. Therefore, slowing the development and progression of vascular calcification is a novel therapeutic target in the treatment of calcium and phosphorus disturbances associated with chronic kidney disease. It seems that cinacalcet, a calcimimetic of the second generation, used in patients with refractory secondary hyperparathyroidism can slow the progression of vascular calcification and potentially reduce the cardiovascular risk. This paper reviews the current literature on the pathogenesis of vascular calcification and the potential impact of cinacalcet to reduce cardiovascular risk in patients with end-stage kidney disease.
Authors and Affiliations
Marzena Żelaźnicka, Piotr Kocełak, Magdalena Olszanecka Glinianowicz, Jerzy Chudek
Keywords
Related Articles
- EP ID EP66783
- DOI -
- Views 147
- Downloads 0
Prokalcytonina (PCT), współczesny wskaźnik infekcji i stanów zapalnych
Prokalcytonina jest białkiem syntetyzowanym w odpowiedzi na zakażenie. Jej wytwarzanie w tych stanach jest stymulowane przez mediatory reakcji zapalnej oraz toksyny bakteryjne. Rutynowe oznaczanie stężenia PCT jest przyd...
The genetics of dementias. Part 1: Molecular basis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)
Frontotemporal dementia (FTD), characterized by neurodegeneration mainly in the frontal and temporal lobes, accounts for ca. 10–15% of all dementias. In 1892 the Czech-German neuropsychiatrist Arnold Pick reported the fi...
The importance of selected spices in cardiovascular diseases
Cardiovascular diseases are the leading cause of death worldwide. Literature data indicate that, due to these diseases, approximately 17.5 million people died in 2012. Types of cardiovascular disease include ischemic hea...
Poziom wewnątrzkomórkowego glutationu oraz jego wypływ w komórkach ludzkiego czerniaka i raka szyjki macicy o zróżnicowanej oporności na doksorubicynę
Long-term use of estrogens: benefit or risk
Estrogens are widely used in hormone replacement therapy, gynecology, urogynecology and rarely in dermatology. Non-therapeutic use of estrogens is very widespread. Estrogens are used as contraceptives, which cause a lot...